Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford today announced a partnership with Danaher Corporation to develop a new test to enable precision medicine care for sepsis, a pathological immune response to infection that accounts for one in five deaths globally each year.

Floor and beds in a stretcher in a hospital environment ©

The test will build on research from the laboratory of Julian Knight a Professor of genomic medicine at the Nuffield Department of Medicine and leading expert in sepsis biology. The novel test will leverage rapid molecular diagnostic technologies provided by Cepheid, a Danaher subsidiary, to pinpoint different subtypes of sepsis and allow the development of novel personalised care paths including which targeted therapies are most likely to help. 

Sepsis is a serious condition that occurs when the immune system fails to react normally to an infection and damages tissues throughout the body. If left unchecked, it can lead to complete organ failure.

Currently, doctors cannot accurately predict which patients are most likely to develop sepsis after an infection, nor can they determine which early-stage cases of sepsis are most likely to become severe or life-threatening, and by what mechanisms of immune dysfunction.


Read the full story on the NIHR Oxford Biomedical Research Centre website.